palbociclib,pembrolizumab
pfizer,merck
['sclc', 'keynote-091', 'pearl', 'nsclc', 'pembro']
#asco22 discussion of pearls (keynote-091, 8-15), a phase iii study of adjuvant pembrolizumab in resected nsclc. the study did meet its primary endpoint (dfs hr 0.76). notes that not all pts received chemotherapy, even those where it is considered standard. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him